TY - JOUR
AU - Ye, Yumei
AB - Cardiovasc Drugs Ther (2016) 30:539–550 DOI 10.1007/s10557-016-6701-2 ORIGINAL ARTICLE Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine 1,2 3 2 4 1 Yochai Birnbaum & Gilad D. Birnbaum & Itamar Birnbaum & Sven Nylander & Yumei Ye Published online: 10 November 2016 Springer Science+Business Media New York 2016 Abstract the effect of ticagrelor + rosuvastatin. The ischemia- Background Ticagrelor inhibits the equilibrative-nucleoside- reperfusion injury increased myocardial mRNA levels of transporter-1 and thereby, adenosine cell re-uptake. Ticagrelor NLRP3, ASC, IL-1β and IL-6. Ticagrelor and rosuvastatin, limits infarct size (IS) in non-diabetic rats and the effect is but not prasugrel, significantly decreased these pro- adenosine-dependent. Statins, via ecto-5′-nucleotidase activa- inflammatory mediators with a trend to an additive effect of tion, also increase adenosine levels and limit IS. the combination. The combination also increased the levels of Hypothesis Ticagrelor and rosuvastatin have additive effects anti-inflammatory 15-epilipoxin A . on myocardial adenosine levels, and therefore, on IS and post- Conclusions Ticagrelor and rosuvastatin when given in com- reperfusion activation of the NLRP3-inflammasome. bination have an additive effect on local myocardial adenosine Methods Diabetic ZDF rats received via oral gavage; water levels in the setting of ischemia reperfusion. This translates (control), ticagrelor (150 
TI - Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine
JF - Cardiovascular Drugs and Therapy
DO - 10.1007/s10557-016-6701-2
DA - 2016-11-10
UR - https://www.deepdyve.com/lp/springer-journals/ticagrelor-and-rosuvastatin-have-additive-cardioprotective-effects-via-V2Hq3FmiS0
SP - 539
EP - 550
VL - 30
IS - 6
DP - DeepDyve
ER -